Current Issue : January - March Volume : 2021 Issue Number : 1 Articles : 5 Articles
Metformin is the first-line medicine for the treatment of type 2 diabetes. Drug interactions\nbetween metformin and other drugs, food, or beverages cannot only cause changes in the\npharmacokinetic profiles but also affect the efficacy of metformin. The purpose of this study was to\ndevelop a rapid and reliable bioanalytical method for the detection of plasma metformin concentration\nin humans. To remove interfering substances in plasma, acidified acetonitrile (acetonitrile containing\n0.1% formic acid) was added to samples. Ultra-high-performance liquid chromatography (UHPLC)\ncoupled with high resolution mass spectrometry (HRMS) was used to analyze metformin and its\ninternal standard (metformin-d6). Analyte separation was performed on a BEH HILIC analytical\ncolumn.................................
Lekethromycin, a new macrolide lactone, exhibits significant antibacterial activity. In this\nstudy, a reliable analytical ultrahigh-performance liquid chromatography electrospray ionization\nquadrupole Orbitrap high-resolution mass spectrometry (UPLC-ESI-Orbitrap-MS) method was\nestablished and validated for the detection of lekethromycin in rat plasma. After a simple acetonitrile\n(ACN)-mediated plasma protein precipitation, chromatographic separation was performed on a\nPhenomenex Luna Omega PS C18 column............................
The purpose of this study was to develop, optimize, and fully validate a high-sensitivity\nmethodology using UHPLC-MS/MS to simultaneously quantify hesperidin and naringenin in\nmicrosamples...................................
Enhancing drug extraction from human plasma is a challenging approach that critically\naffects pharmacokinetic and any further clinical studies based on the drug..........................
Inflammatory bowel disease (IBD) is a chronic relapsing disorder modulated by numerous\nfactors. Recent failures of drugs targeting single factors suggest that multitargeting drugs could be\nuseful for the treatment of IBD. Natural medicines may be an alternative option for the treatment of\nIBD, owing to the complex nature of the disease. However, most natural medicines have poor in vitro\nand in vivo translational potential because of inadequate pharmacokinetic study. KM1608, a mixture\nof the medicinal plants Aucklandia lappa, Terminalia chebula, and Zingiber officinale, was examined for\nits anti-colitis effects and biodistribution using bioimaging. Dehydrocostus lactone, as a marker\ncompound, was analyzed to assess the biodistribution of KM1608. KM1608 significantly attenuated\nthe disease activity of dextran sodium sulfate-induced colitis in mice and suppressed inflammatory\nmediators such as myeloperoxidase, proinflammatory cytokines.................................
Loading....